Insignis Investigations has now earned the right to display the coveted IQ Verified quality shield and standard BS102000 logo to demonstrate its conformance to the standard.

The positive regulatory response marks a pivotal step forward for Insignis and comes after a successful phase I study demonstrating that IN-001 achieves epinephrine pharmacokinetic (PK) profiles ...

MSCI currently leverages Insignis’ technology in its InvestorForce product line and plans to expand its use to further automate the collection and integration of data across its risk and ...

Innovative Health Sciences will be presenting its breakthrough versatile and low cost non-electric infusion system at Medica, November 15 – 18.

Under this IND, Insignis in collaboration with its strategic partner, HLK Pharmacin, is prepared to initiate a Phase 1 study with IN-001 (known as HLK-0006 within HLK Pharmacin) and intends to ...